Literature DB >> 33127851

CREB Coactivator CRTC2 Plays a Crucial Role in Endothelial Function.

Hideaki Kanki1, Tsutomu Sasaki2, Shigenobu Matsumura3, Tomohiro Kawano1, Kenichi Todo1, Shuhei Okazaki1, Kumiko Nishiyama1, Hiroshi Takemori4, Hideki Mochizuki1.   

Abstract

The cAMP pathway is known to stabilize endothelial barrier function and maintain vascular physiology. The family of cAMP-response element binding (CREB)-regulated transcription coactivators (CRTC)1-3 activate transcription by targeting the basic leucine zipper domain of CREB. CRTC2 is a master regulator of glucose metabolism in liver and adipose tissue. However, the role of CRTC2 in endothelium remains unknown. The aim of this study was to evaluate the effect of CRTC2 on endothelial function. We focused the effect of CRTC2 in endothelial cells and its relationship with p190RhoGAP-A. We examined the effect of CRTC2 on endothelial function using a mouse aorta ring assay ex vivo and with photothrombotic stroke in endothelial cell-specific CRTC2-knock-out male mice in vivo CRTC2 was highly expressed in endothelial cells and related to angiogenesis. Among CRTC1-3, only CRTC2 was activated under ischemic conditions at endothelial cells, and CRTC2 maintained endothelial barrier function through p190RhoGAP-A expression. Ser171 was a pivotal regulatory site for CRTC2 intracellular localization, and Ser307 functioned as a crucial phosphorylation site. Endothelial cell-specific CRTC2-knock-out mice showed reduced angiogenesis ex vivo, exacerbated stroke via endothelial dysfunction, and impaired neurologic recovery via reduced vascular beds in vivo These findings suggest that CRTC2 plays a crucial protective role in vascular integrity of the endothelium via p190RhoGAP-A under ischemic conditions.SIGNIFICANCE STATEMENT Previously, the role of CRTC2 in endothelial cells was unknown. In this study, we firstly clarified that CRTC2 was expressed in endothelial cells and among CRTC1-3, only CRTC2 was related to endothelial function. Most importantly, only CRTC2 was activated under ischemic conditions at endothelial cells and maintained endothelial barrier function through p190RhoGAP-A expression. Ser307 in CRTC2 functioned as a crucial phosphorylation site. Endothelial cell-specific CRTC2-knock-out mice showed reduced angiogenesis ex vivo, exacerbated stroke via endothelial dysfunction, and impaired neurologic recovery via reduced vascular beds in vivo These results suggested that CRTC2 maybe a potential therapeutic target for reducing blood-brain barrier (BBB) damage and improving recovery.
Copyright © 2020 the authors.

Entities:  

Keywords:  CREB; CRTC; endothelial cells; p190RhoGAP-A; stroke

Mesh:

Substances:

Year:  2020        PMID: 33127851      PMCID: PMC7724130          DOI: 10.1523/JNEUROSCI.0407-20.2020

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  65 in total

Review 1.  Role of GTPases in control of microvascular permeability.

Authors:  Volker Spindler; Nicolas Schlegel; Jens Waschke
Journal:  Cardiovasc Res       Date:  2010-03-17       Impact factor: 10.787

Review 2.  Rho GTPase-activating proteins: Regulators of Rho GTPase activity in neuronal development and CNS diseases.

Authors:  Guo-Hui Huang; Zhao-Liang Sun; Hong-Jiang Li; Dong-Fu Feng
Journal:  Mol Cell Neurosci       Date:  2017-02-03       Impact factor: 4.314

3.  Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133.

Authors:  G A Gonzalez; M R Montminy
Journal:  Cell       Date:  1989-11-17       Impact factor: 41.582

4.  CREB downregulation in vascular disease: a common response to cardiovascular risk.

Authors:  Irene E Schauer; Leslie A Knaub; Monique Lloyd; Peter A Watson; Catherine Gliwa; Katherine E Lewis; Alan Chait; Dwight J Klemm; Jody M Gunter; Ron Bouchard; Thomas O McDonald; Kevin D O'Brien; Jane E B Reusch
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-02-11       Impact factor: 8.311

5.  ROCK inhibitor Y‑27632 protects rats against cerebral ischemia/reperfusion‑induced behavioral deficits and hippocampal damage.

Authors:  Lihe Li; Baoyang Liu
Journal:  Mol Med Rep       Date:  2019-08-09       Impact factor: 2.952

6.  CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo.

Authors:  Olivier Dormond; Alan G Contreras; Esther Meijer; Dipak Datta; Evelyn Flynn; Soumitro Pal; David M Briscoe
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

7.  CRTC2 (TORC2) contributes to the transcriptional response to fasting in the liver but is not required for the maintenance of glucose homeostasis.

Authors:  John Le Lay; Geetu Tuteja; Peter White; Ravindra Dhir; Rexford Ahima; Klaus H Kaestner
Journal:  Cell Metab       Date:  2009-07       Impact factor: 27.287

8.  Complement peptide C3a stimulates neural plasticity after experimental brain ischaemia.

Authors:  Anna Stokowska; Alison L Atkins; Javier Morán; Tulen Pekny; Linda Bulmer; Michaela C Pascoe; Scott R Barnum; Rick A Wetsel; Jonas A Nilsson; Mike Dragunow; Marcela Pekna
Journal:  Brain       Date:  2016-12-12       Impact factor: 13.501

9.  Use of the mouse aortic ring assay to study angiogenesis.

Authors:  Marianne Baker; Stephen D Robinson; Tanguy Lechertier; Paul R Barber; Bernardo Tavora; Gabriela D'Amico; Dylan T Jones; Boris Vojnovic; Kairbaan Hodivala-Dilke
Journal:  Nat Protoc       Date:  2011-12-22       Impact factor: 13.491

Review 10.  Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21.

Authors:  Bryn M Owen; David J Mangelsdorf; Steven A Kliewer
Journal:  Trends Endocrinol Metab       Date:  2014-12-01       Impact factor: 12.015

View more
  1 in total

1.  MiRNA-132/212 regulates tight junction stabilization in blood-brain barrier after stroke.

Authors:  Haomin Yan; Hideaki Kanki; Shigenobu Matsumura; Tomohiro Kawano; Kumiko Nishiyama; Shintaro Sugiyama; Hiroshi Takemori; Hideki Mochizuki; Tsutomu Sasaki
Journal:  Cell Death Discov       Date:  2021-12-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.